StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)
October 30, 2024 4:03 PM
BofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Citi Removes Two names from 90-Day Catalyst Watch Lists
October 31, 2024 4:06 PM
Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)
October 30, 2024 4:16 PM
Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
October 30, 2024 11:01 AM
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
October 30, 2024 11:00 AM
TD Cowen Reiterates Hold Rating on Edwards Lifesciences (EW)
October 28, 2024 2:20 PM
Edwards Lifesciences (EW): Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
October 28, 2024 11:12 AM
Edwards Lifesciences (EW) Quickly Falls to Low
October 28, 2024 11:11 AM
Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
October 28, 2024 11:00 AM
Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform
October 28, 2024 8:19 AM
Edwards Lifesciences (EW) PT Raised to $85 at Barclays
October 28, 2024 6:12 AM
